Asymptomatic hyperuricemia
Conditions
Interventions
Placebo group:Microcrystalline cellulose, once a day, 1 bag each time (3.146g per bag), taken with meals or dissolved in water after meals, for 12 consecutive weeks.
Investigational Product Group:Magnesium citrate compound, once daily, 1 bag (3.146g per bag), taken with meals or dissolved in water after meals, for 12 consecutive weeks.
Sponsors
The First People's Hospital of Kunshan
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18–70 years, both males and females; 2.Meet the diagnostic criteria for asymptomatic hyperuricemia; 3.Kidney stones (<=10 mm in diameter) confirmed by ultrasound; 4.Sign the written informed consent form;
Exclusion criteria
Exclusion criteria: 1.History of gouty arthritis flare; 2.Patients with severe dysfunction of the heart, liver, or kidneys; patients with malignant tumors; or patients with psychiatric disorders. 3.Current use or planned use during the trial period of any medication known to affect uric acid metabolism, including but not limited to allopurinol, febuxostat, benzbromarone, probenecid, low-dose aspirin, diuretics, pyrazinamide, and levodopa. 4.Women who are pregnant, breastfeeding, or planning to conceive during the study period. 5.Known or suspected history of allergy to the investigational product or its excipients. 6.Poor compliance as judged by the investigator, or any other condition that, in the investigator's opinion, makes the subject unsuitable for participation in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum uric acid; | — |
Secondary
| Measure | Time frame |
|---|---|
| Urinary pH;Urinary Oxalate;Blood Pressure;Serum Creatinine;Estimated Glomerular Filtration Rate;Exercise and Diet Questionnaire;Serum uric acid target rate;Maximum diameter of the kidney stone;Adverse event; | — |
Countries
China
Contacts
Public ContactGuo Zhengli
The First People's Hospital of Kunshan
Outcome results
None listed